GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Other Stockholders Equity

Royalty Pharma (MEX:RPRX) Other Stockholders Equity : MXN0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Other Stockholders Equity?

Royalty Pharma's Other Stockholders Equity for the quarter that ended in Dec. 2024 was MXN0 Mil.

Royalty Pharma's quarterly Other Stockholders Equity stayed the same from Jun. 2024 (MXN0 Mil) to Sep. 2024 (MXN0 Mil) but then increased from Sep. 2024 (MXN0 Mil) to Dec. 2024 (MXN0 Mil).

Royalty Pharma's annual Other Stockholders Equity increased from Dec. 2022 (MXN0 Mil) to Dec. 2023 (MXN0 Mil) and increased from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil).


Royalty Pharma Other Stockholders Equity Historical Data

The historical data trend for Royalty Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Other Stockholders Equity Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial - - - - -

Royalty Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Royalty Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Royalty Pharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma Business Description

Traded in Other Exchanges
Address
110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.